-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OknMstVVU0mJCtgogaWaKAjkhQ6CjSgp3TzxKHEMu//IWlvVozqsZPe0WOhLpAvb
 o+q3PFZGsmcyyc8MamKqsg==

<SEC-DOCUMENT>0001193125-10-074550.txt : 20100401
<SEC-HEADER>0001193125-10-074550.hdr.sgml : 20100401
<ACCEPTANCE-DATETIME>20100401103834
ACCESSION NUMBER:		0001193125-10-074550
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100401
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100401
DATE AS OF CHANGE:		20100401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10722147

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): April&nbsp;1, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>On
April&nbsp;1, 2010, ARCA biopharma, Inc., or ARCA, issued a press release announcing that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million
through the sale of 1,075,000 shares of ARCA common stock in open market. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. <B> </B></FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma raises $6.8 million in first quarter of 2010 through at-the-market offering of common stock&#148;, dated April&nbsp;1,
2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;1, 2010 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>ATRICK</SMALL> M.
W<SMALL>HEELER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patrick M. Wheeler</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Acting Chief Financial Officer</B></FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma raises $6.8 million in first quarter of 2010 through at-the-market offering of common stock&#148;, dated April&nbsp;1,
2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g11567g70m98.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U>
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA RAISES $6.8 MILLION IN FIRST QUARTER OF 2010 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THROUGH AT-THE-MARKET OFFERING OF COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO,
April&nbsp;1, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010,
through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The proceeds from this equity offering, together with the actions we have previously taken to reduce costs, have significantly improved ARCA&#146;s
financial position,&#148; said Patrick Wheeler, Acting Chief Financial Officer of ARCA. &#147;The additional equity also improves our balance sheet, which we believe will allow us to regain compliance with NASDAQ&#146;s Continued Listing
Standards.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush PacGrow Life Sciences acted as ARCA&#146;s sales agent for these transactions. The shares were issued pursuant to
ARCA&#146;s shelf registration statement. A prospectus supplement relating to the common stock offering was filed with the Securities and Exchange Commission on December&nbsp;8, 2009. As of December&nbsp;31, 2009, the Company had 7,620,448 shares of
common stock outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted
heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding the issuance of common stock through the equity distribution agreement; the impact of the offering proceeds on the Company&#146;s financial position; the timing and outcome of any potential plans defining how the
Company intends to regain compliance with NASDAQ Continued Listing Standards; regulatory review and potential approval of the Company&#146;s New Drug Application for Gencaro; the prospects for ARCA&#146;s providing sufficient information in a timely
manner as requested in the FDA&#146;s Complete Response Letter for Gencaro; and the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual
results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources
and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the
regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s
annual report on Form 10-K for the year ended December&nbsp;31, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g11567g70m98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g11567g70m98.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P#3`P$1``(1`0,1`?_$`+(````'``,!````````
M```````%!@<("0H!`@0#`0$```8#`0```````````````0(#!@<(!`4)"A``
M``8!`P($`P4&!`8#`````0(#!`4&!P`1""$2,1,4"4$B%5%Q,A8788&10B,D
MP5(8"K$S0[8W=W)&&1$``0,"!`,$!P0(!P````````$"`Q$$(1(%!C%!!V%Q
M(A-1D:'!,A0(@;%2(_#1X7)3)!4)\4)BHC-C-/_:``P#`0`"$0,1`#\`U,\J
M.5MK2LTICG%TD,''0J_TZPV5CLI*/9`"F!S'1R_:<K%@S,'8=4@>:<^^PE`-
M>3/U<?6!N_3]PS]-^F$\,,43/YJ[:N;!45'(E%HF%4XF<MA]/])N(DUG747Y
MI:96JG+BE47C4@HRAIFRO!?3+EZ^=N%O[UXY<+O71RJCL8ZR[@QEU#]FP_,(
MCMKS;L;7<.[]4\V\DDN5E=7S')3,Y5QIV5,T7CK"PMFQP.3R\M>[E3V#G0^&
MGQIIC&*MU0.I(MVW:8.X-Q4(<OAX@)!`0'PV$-M95T[HMK=YJ]G#)&Y)IIF,
M1*<4>J(IU#MQ6D-B]&N3-0+%L5.U5%!*DH)622RZQRD["(M6X#WF4`=]@4W*
M3_YF*'QUP-4Z,ZK;W<T36.\BU9*URTX+2I/;;JB\NVQ3C[Q"(&L]+?A)P$I)
M0SY)43%<Q;APQ<`<@AX*H#Y@=@`'<`=Y!^("&K%MM2W;LR\BU?:[UM];A=7,
MJ88+]GH.[S:1K-FZUU"BL=Q3D69\2.3\UD:0''.05$W5G28KO(.P@5%!2=39
MI$,\822294RC))(@"A5$R@"I"F[@W#KZR?1O]5VJ]4[V7IQU%E9)N-(T=$],
M,S:*F3BM5P7UFO/4;8=OH<::EHU?D7+1R>AW9Z$X%@H"(CMML&P]?WA_CKT;
M<V1'5K5E*&(WTBD;"W@K55>]/\3MJ!$ZF[=OF+W=0V_%^(!`0$!)\P&W#I^W
M;0%:&)?<?H66_<"S1P?C(J/0)C&K$<UV\HRQUU+A>:\+97(U21CP2%JV"KMY
M%(4U2**'4%!QW`';H"S'0`_?L'Q'QV#XC\?#0%97)_G=GGBXYNUCGN`^7<@X
M6IJBRA<P8\R9CJ;:.X%NFBJI99.DH`2TUQ@053@L+A$01!/<P@4=P`A-C#W]
M*_G>[1F.,&\)N063,@2S9P\9UF%LU`2<"R9)HG>OW#LSU=HRC6A5R>8X7.DD
M7N`-]Q`-`2?O?N-\F<05YW>LM>U]R+KU`B&QG]@LE.R3B[)KZOQB11.XD)"N
M5QZ,@FV:)$$ZI^A$RAN8P;Z`D9P[]Q/B[SDCWWZ)W-X6X0[)&2L&-;DQ_+]\
MAV#CL!.2",.X=,Y>&.H<"@Z8.'*!1$`.)!,`:`G'H!O<GY8QKA6F3.0\LW6O
MX_I%?0]1+62ROTX^.;E$!$B"0FW6?/UQ#9)LW*HX6,(%(0P]-`50P'NW6+D;
M:)>I\!N(.5^2S6%>'82F6;=*1V&L01CTIC`0%IZP)/I!9-0H`<$A11=B0=_)
M#<`T`[,IF#W;8>-4F"\-^*EH.1$RZM6KO):Q(654I`'N10>SE$90CI<"AVAN
ML4!'8`T!#:L>^7/PV>Z3QLY%<),B8-R1;+Q5J0]^H7Z-6:0IK;.-8!C/E8R=
M;C3R\#ZAV!BN6JRJ2Y?^68>H@!H/*':&WQ#<IAV'YCE'M.;KU'N,`CO\=`<Z
M`B?S9Y3P'#?C5D_/4TS;3CRH1+=&IUAW(&C$K5=IIT$=5JV#M)-5=`CZ04[U
MSD(<Y&R2I@*/9L("NXJY^@>4?'K$V?*X@BQ8Y)J#&:?1"+OUA:]8B'48V:O'
M6$I#JJPT^T<MQ.8I#F!(!$H;Z`D%H`:`SJ1L*]LEDDE@2%\HM,2)UC@L/J5U
M%WJZJJYTA$BRJ@G$1W`!^X=?,%9:5>;MW%=QVD4ERLES(CW,7*J_F.2BU1]3
M=&6YBTZV;)(UE%C3EV(3-QOCUC,%;1$@4D7.[`6+D'2/E-W2@CV?2Y0NQ#(F
M6*'])<0#M-T,&PAK?#I1TQL]0@MM$U!/D]P-=_+9V_EO1$16M<N%55U:TIQX
M&*-=UE&O=+;/S6"8R(JU<B\\JX41$Y47F2IC:;!Q+NF2-D=L86;@URL)1@\5
M3%W(,H@3A%OTFR7G*K"*(E)W"!0,4`'??6Y%ALK2-*U;1]5W)/;66I64M)8E
MH[S516JQS&U:J)7C7-7TEARZE<S/D99(YT4C5R*O^['#'[@L?XH1<P3MI7O0
MR3N=E3&>/6[@@-8V$9F.Z01>+*@F8GGKG*HH';L(I@'PUU^M=)GWNBW;-NK%
M=W&HWKG2R<&V\#D:BJJ8T6E5JJIP.18:PZ.5K+Y<L428(G%5]M??4B3DNDQZ
M7G1=>24DQ1.)'<LDV,9615#KV,FQ"F]'%-3_`"%$P`=0?F$=M:2]7>E^G?*O
MLMNN6YC8BU>UF5U4XU6KJI7L,C[<UJ%\B.D5:JO!5KZ^T:'`D:\@^1>+TQ+Z
M=0UG*W5*4Q1-Y:K1Z@JFIV&,`"=)0P&#H.P^&L)?3397^WOJ3VM;RHD=Q+J3
M8GY:IFC<J?%Z7<<?875O>];?;1N6M:Q(V1JJ43&M._N+VP#;?Q'?[?A]WV:^
MAG+ED545:*JX<L*&H4"9F><OQJISJ<K$5>;7(^/XG\7\MYP<`5Q,5BN*L:1$
M;=Z]@R%8CE@Z3"-&P?.[6>3[U$13*`F\HAQV^70&*W)=#S+[6/-?C7F.\2LI
M.6N8@<?9_MDJL7TPS3Z\+ND\YTIPL0X`O].=R,@V,8PCW@JF/Q#0&^*MV*'M
M\!"6JO/$I&`LL/%V"$D$#`=%]$3+)&1CWB0AT\I=JY((?MW#X:`.M`-#R"02
M<X#SDDN0JJ1\.Y,(9,Y2&(9,])FTCIB42B!B*$.(&`?'<?@.V@,?'^W%*0W-
M"\;II@!..-A,F`$#9,36VE%$$]]^P.T1#I\!V\-`;9%$DG)1163341.!DU$3
MID.DHFJ44E4U"'*8IR*)G$#`.X"`B`]!T!@%KKB1XW^\H,3A$%(Y"L\TG-)@
M8B(\S9Y5;5>2P\_510;$[5(I:)E5VXI"`)@"11#J0@@!OKFY:,K\5+STR]0C
M(:#CY"7EI%T<$VT?&1C59Z^>+J&V*1%JU0,<PCX%*.@,15TR;E;WOO<+JV*6
MD[,0'':%L,P^K,`S6418T_$-65*$_?GK(H@V<WZXM`(1!RX`5$%'Z*"7:1'Y
M@-GN(\0XYP3CVLXMQ35HRH42IQJ49"0<:@FDFFFDF0JSUX<I"K/)605**KAR
MJ)EUU3"8YAZ``#C]H;"'40'??YC;]?CT$.H!T^[0%<'N4<(&G+_#\0\I,57F
MG(G$-IK5ZPG;I-9.&%"1@K`PE9*GRTZDW570J]B9(*=Y!*H1-T1)4``Q>H%C
M#,[E1FT4>I)HO5&R!WB21_,23>&3*9T1)02D\Q(K@3`4VP=P==NN@/2&WQW^
MP-@WW$?`/WCH#.-[KU=OO/;,UNX@8CD%@@^(7'^T<ELF`PV71L&8YB..VQ-C
M98IA\@[U6OHO7!!W\Q,SP1[=R@.@&L_VX?)D)"M9EXFV!Z;UE<D/U@QPV<J%
M`30DX9I%7N+9@8VX)Q\V#-YY92_*9XL;X#H#46'@'W`/\0WZ;>)?L'XAH`:`
MH5H,<@ZGGQAD8YD89%X8JCU5=,$Q%TJ!3G!-LH<P`/V:^</I;I%U<;LGDBG@
M1Z7<GB=(D=/S'<J.^\V^W'/'\@U)&O\`^-O!.Q.TLGH:RK*$>*R,W4;8C&1+
M^19QKE560E_.C&"[M(&#A9LW7#^HB'<F)A+V>``.XCZN=/[J;1]OWFJ:M=:9
MJEQ:6<LL%LDB)/F9&KE5F#E7@E$1$JI@#5ODY[B.VC2=JRR97*K:-RU3CCW\
MAE\26A"PN_S#8'7K)&55%Z[7<*E%03+`0VQ2!U31+W`4@!T[2ZP7TIW+IVZM
M3AU_6[B22ZN[E]<RYFP-S953E\-/%PHE%YEUZY:-TQD5K:(U8V,HU4XK7C^T
ME?(6.$27B0C"(B=PNW8N6Q#`9)\W>*%;+MU4_P"<#)J;[>/36XM]N_;=IJEE
M;V$C&P2R)"L:.HVZX)BN-$QI6BE@/LKITJR2)1HS^7F1SI/F#:U4Z+BP\T@P
M\2LXCP[```!-\+)D==T<=NO><0WUAKK):2W394TK4-)@@RKX&R(B\\.\N';D
MR-E2L<ZNKQR5]_W$,\7Q[=GR)Q>0KR/7/^:T##Z-14P''R'(`8H+(I'$``-M
MQ^S6@O2BP?:?55M-OF12I_58E5S'HY*JY>:(F/890UM^?9=X[*]O@=@Y*+P]
M!=1KWM=\?VN]QJ[;?^=.\&HE8HJYG7:J\F/<<XQ</9:S5Z)Q!QL,GRKY"GL$
MU'P\1*6EBFD7$]*>'D'39NY<(N':+LZ`")A1=B8Q=B".@&?]_P!Q]C'-O%^J
M9CIEWQ_.WG`UJ%=TRB+A5WLS(X\O2C6#L;9LV:2BSATG&3(1SP2)%.<")*&`
M-M]`2$]A[DL?.'"YACF>D0=WCCA,FQJ_3.H!W"U)<D4EL?/S]_\`5,@2*458
M%'<0W8>.@+L=`-/GS_P/G#_T_DO_`+-F=`8B_8\S>RP)R=MEP?XXR]DYJ]P3
M+0:T+A6BNLA6J.!S:*FZ+,/8-F\:K)1"0-!(=;<PE.8@=H]V@+P,T^_[@^,5
M>8XP=B;*,IF]],(4Z(9YOAV6&JC3[;(+I1[-S?G$]*+34;'QCQRFJY3%LEW)
MAN)R)CWZ`5/MU>T`^P3E%URXY67"#RIR3FYJ;M\1%UTRKZC4>P6U=9_+V5*2
M?M4%[':A._73:*E219L$C_T0.<04*!-+W9;?+4CVZ>5DU"+KM9!SCLM<]4V/
MY:J#*V3T16Y0X'V'8#QDHL01^`&T!1-_MI*M&.,H<I[D<J8RD'0<<52-5%,#
M*(QD_89Z6D.U0>H>H<0+8!$/Q"0?LT!KJT`-`#0`T`V&:LJU?!>)<BYENKE-
MI5L8T^>NDPH<P%%5O!,5'B;!#<I^Y[*.2$;MP`#&,LH4"@(B`:`JI]HU]5XG
M!MZY.YDR'CZ/SAS3R7.YRO+*6N-<:24)5WCAQ'8ZJ:S5Y)IN&;6'K916(@<"
MF3!UVB`;;`!GKL=AA_;3]X(UNI<U&2&)6F5"V`%JY*L)2)5PCFHY0L<*#B/7
M<M!+5C32X`D8>],\:0P@`&`=`;L6CEJ]:-7C%PF[9.VZ+IFZ24!5)TU<IE7;
MN$E2B)5$ET5`,40Z"40VT!Z-`9\Z?),6,^]]0NL1,LHZ$44A(=90"O%1`A#.
M!%),3#_-L/;\`'7S/[,OM/T'=<R7J.D;\W)S_P"QQN?JD%[<VC&Y$IY;?N0L
M2Q/<D5#>3$QL3"Q[5--2:L4PH>6>(,5>BJ;AV\$J0+.@W221;I`!Q-ML&V^O
M4GH[O>%LC'Z%!I]KHT;?YRXN<7LCD3*Y&<$\:(J(GI,';FTF2&173/7SW(F1
MB88UP7U\U$@[P)*)3);'A^PQ+.OV>7?DCJM:E58]RBZ*HHLZ)#/6R+TAXPIQ
M'RDSE!0A?EW'5EZM]/.LVFLR[JZ.:G:6NCZS/)2PO,&J]J(JOB<CDHCU=PR\
MDQ.39[QT^*W99:S!62W:K72)C55P:E%QK[!T*74%ZP9A9<B6>.=&^HNFL62#
M1<OHF'F&C<Y2.IARX*BJJ9DJ81*4B8%#\1AVUF38NS-1V?;VFYNHFIVZHR7R
MT;`F9+>2J>*JN3THO+@6WJ^K-OWN9I;:,IZT7T#:Y9NB`+O&=DA8[U94U%$)
MZ"`K([]%0`%!VF;^YC)-HNE\P&'RS`/0-M8DZZ[WTV.22'=.GP23.1<LUO@V
MG)5P7%4HJXER;:L+Q'-R3*C<,%Y=F.)%O$3]%UR-Q@5LLHH0;<B)3'1(@;M%
M!<=CE(=0@F#XB4W:.M/^@L]E<_4IM2>P>C[9=993LQ^%>U/>7_N6.6+:%XV9
MV=WEKC]G`O'U]`+OC^UWN-4[;_SIWC>Y;R=5<*XPOV6[N])'U3'-2G;A.N53
M%(!F,(P6>&;(B;H+EXJ0B*0>)E5"E`/FU$K%&GMC\,L6\K<59'YJ\Q,,4G*F
M1>5^6+1DBL(9"K[2>+5,=,GZT-5V$(F_*<6+-\5L<Y0`I?-;)(&'P#0%B5D]
MKG@)/UV>@VG%'"D`ZFX:4BVT]"42*93,([DF:S%O+Q+Y!,J[.0CE%P634(("
M0Q`'X:`R\>TADVP<'?<KL''3(KD8V.OTY8N/%S*NIV-4[M!2SQ;'LV=$Q@(G
MZZ2;>F3$/`DF`?MT!N!`1W-ON&QMMA#;;H&X?N'0#49\_P#`^</_`$_DO_LV
M9T!CT_VX@F_UG7H`,8H?Z;I_P$0_^X4<WPZ#\Q`\=]`67^_![>3?*V.U^8.)
MJ^"V2L8Q`-\N0\:@<SR]XQ9AV_F-PV;]BDA/4(JAU#GV.HO%&5*(B")"B`>^
MQ?[BRN><?)\3LN3QG>8L409%L?S<DY\Q[D/%T>5)NFV5<+[*/K11DCII+@`G
M4<1HI+B(B14=`7%<O<*&Y&\8,ZX/1432?Y'QO8X*&56[?)2L(,S/JXLMW%-L
MBG.M&XG$`[NW?;;Q`#(G[$N;2\<.=%FPCD\%*FIF2`?8F=,IOS&"D1E>D3JS
MV"AGJ*O:D@\DG2$A'I`8=S.5$R%_'H#;SH`:`\<B_9Q3![*2+ILPC8QFZD9)
M^]6(W9L6#)!1R[>.G"@@1!NV;I&.<YOE*4HB.V@&SP?FJA<B,657,V+WK^4H
M-V2DW58E).-<PR\JQC)F1A#2*3)X4K@D>^<QIU&RI@`%VYB*!T,&@*?_`'=K
MG,9WR+Q1]M"A.UTYCDGD2&NN95X\RAEX7"=&DADG)GGE&#R4I-S&.78`<``1
MC2!U`^V@)WH>V5[?23=!/_1W@-04$4T2J.:##JKG*@0$DS+N54E%%%3$('><
MPF,)MQ$1'0%$GON>WMAC$.$\:9]X]8DI>,8>K6Q>C96B:5")PK![#W%(IZS8
M'[6/(4IEHZ=8>D.J/S"21+OOL&@+:?9GY-J<D>#>.2SLD$C?<-&4PS=#+K&,
M]7-56S4:E,NP.`J!]7ICEF<QC=1724#0%K>@,^>:*)+XER=8ZY()+IMA?N)*
MO.E#`4)6$?+'<MW#1;8"*`EW@FH`?,FH':(:^;KKUTVU;I#U.N]JW<3V6B*L
MT<R(N6YSJKLM<.[F;A[1U^#<6D?.P.:RY:U$5O<@?U?)+D$6<9YG9'I'3(DW
M!0`2!=38//7*`CYBP&#YC#\`#78;0ZJ7++>WT/4&>5IKG>-OX>5/5C]IUM_I
M4<SW+$GB=B[][]*$G(/-;0UFJOE/!^FUU6)CV:8G`Q010,!GC@Q/#U+UXH<Y
MQWZE`@?#6W&W?J'L/Z]I+(7HVPTN>-C4KQS.0LVZVBYS9'HGQ-=7U4^X3CC,
M""C&=A578F;R)S/FNQO+\B78'.HF<OCT>(J'3$?CTU:M]UPLUT75-.61*W%W
M+(E5[&E>VVF_);.1N/NKP(X6S(SY\V"-.91RT2\U5`HF[5&@F`"F*@<-Q(DI
M^-4GX1/U``UJCO'JG?[CL_Z4Z22:R_$_]%+]T31H'KYK$RT](Z/#:@S5SS1#
MVD&[H8*BBO+RC\Q1*W]<=LNC%1A%3E#=PLLN*A@`-P(GOK/7T1]--7W;U@L]
MT.\6W=%_-=(B+ESK_D[TRISYG1=5->M=+VH[3XW-=>SN5M$XY</UJ7+62?85
M.O3EHE@?J1=<B)&<D2144_G))1E%LUGCDC"%BD'<I*O#((F\MNW2565/L4I1
M$=M>ZD+7JY\SUJUR^#THAJVJN5K,,*8F7GW7N77(#F1B9'CWQ3XI\L5,934B
MSF,GY%LF#[W5E;6SBE0>0U/@8%_$EE`A5))))V]6=)I"IY::94P$IAU7)2Y+
M@7R:Q[D6@X]PA7L.YXPO9,:8DJ[&1J.5<-W.DPL2WK4?%P3IG%7&0C25F<<'
M?'\P@)N/.72W4\LH@;8"8F7LKUK"=!F,C6Z/N$I!0BT>@Y8T.FV*^VAPK)O6
M\>U+'5BK,)*:?@#AR7S#))&*D3<YA`H".@,2WN(TS-7)OFM:N1_%KBCRG@HA
MZG0I1G8)G"ETKTP_O].:MTEKFUASL!4CDC'8-!3*J;SESH"H8"]VP`:0^'?N
M7V7)K+'V->27&+DUA3.4PM%5B0DWV#KZ\Q7/3SD0;$GT[4RBE$*HPE%TC*+D
MD2(H-!/_`,_LV'0'NYN<^HRFT_.6#,9\=^4N9<M/:S:\=MB4[!5\-CUO-V*O
M.(PLFKD%>*3AY*'C22A5C'C_`%?G=O840$1$`,Y?M=)\D^`7)(<LY.X:<HIS
M']CQ_+X]LBM7PY:7MAA$'[^&E6DY'1AH]L622;N8@$U&X*IJ&2/W%'N`0$#9
M#@W.E$Y,T62M-7K.0H>#)(OJO,U_+F,[-CF;,MZ%!1\U6K=RC63B1C5FK\J8
MK)`JU4W,4#B("``8^.<G`3D5P1YM5[)_#JBY(L-2D[$KE?#4KCFJV&UGH$H@
M](>Q8\L;>#:NA^E-E%S))IN1\IY#.O)W[BG#0&B/C=[F[O(I*54<\<4.56!,
MK65[$P#L)+!UZL&,%YV3419IR4=<8M@X4A(5=VIW&-)(H>D3^5100*!A`C#[
MG7LVFY)V]WR3XMS4?COD41=I+66ONGBD!6\D2T6=)5A96,XR*HI4,C-#MD]G
MW8+9V8A#K>6H!E3`=>.?NG9GP)$QV(O<\X]YPQ?<:RDE#)\@X3'$]<,?W1LS
M,+9&9M"]093#-E)K-TP4<.XXSELZ$?,\M$QC%`":[[W=/;P;1IGK'D5'6-SY
M/F)P51I&2[-9%CB7H@A!1E17DP7$>@$.0@E'H/;H"H#GUS8YM<Z*+8<#\(N(
M')>#P]:FSAC<LIV/&T_5;3?H901(:#A&DBBP9UJH2@'#U*JZYW;I(.P2)$,<
M#`6_GS92/;VXX\><,2&*LY9%ME>PM6(:'I&$L1VK(*CN7K$)&Q\FTDIN&CCU
MRM&=6!=3YGKA,W:8RA2F`.H%(/%+D#GBM^XQEGFOS%X?<HHN.R11G]'Q^\JN
M%;U;/T>BBO8PL+#I1K>+%\[8C5HHS9PY;)^;ZI==0Q#%5#8#5G0;O#9)I-9R
M!7V\ZT@[=#M9V+;6>`E:Q84&3TGF))R]<FFC*8AWI0_&W<(D6(/00WT!5=[H
MG(S'TM@[D%Q-)A+D7F#)5OQZ$9"1N.L&WJRU-O8IIFA+U.7-?F\2:K@2#?IH
MNEQ;KKJ(F1%,2@8=M`4!^V!D+FI[>62;/+VCAKR7M^%LFL(R.R/7X7%UQ^MQ
MTC!'5/!W2LHNF`M7LC')NUD5FRWEE<-#@4#@<I1`#21_^J&#NSN_1/FQO]'^
MK>7_`*2LM>9]3]1Y7Y3V^F;?F+L_J]F_H/*Z^HW^70$Z\DXFH66(<L->8)"6
M01,91BZ(HJRDXU8_<!E6$DT[7;<1[NH;BF80#N*.VL9=1^D&Q^K.B/TC=EHL
MJT5&S(J,G9^Y+E=E]2G=:/K^IZ'<I=:<_(Y.+52K5[T(F+^WSC0SE99C=KTQ
M0.?=-MYD.Y\@````I7*D:FJML`?B-N(_;K4"?^W5TK?-YEOJ6JVS?POD29R_
MZL_Y?=3+A3B7PSJSN%J?G16[W^E(\OL15Q[3[H\!J4W,D='(MZ(*1BG)LE!_
MB*8#`)O['KU+JC%_;HZ:0W#+F+7=521CT>F"45S5JE4SXE9W5[7',6-;>#*J
M47PJ=3\`Z2H(F/D:]B.WB"<&&P[@/>7^P'8X;>.DG]NCII++YS]=U3,N;DE/
M%QPS^H,ZOZ[&C$;;P>#AX5]I]8OV_L5-G:;J8M%VF6Y3")V@/H]B58HCU*HL
MS9D<%*;X]I@Z".N;HG]O7HY;73)]5O\`5+MD;JHQ)DC:O8J975)KKK%KSX%@
MMX[5C53DQ57[T)C4VBU3'L(A6Z=",H&(:CN5JR2$IE%.P"BNZ<*=SAZY.4`[
ME5#',(_'6Z^T-A;1V#I3=%VC90V=BE%7(U$<]>&9ZI\2KS,87VI7NK7'S=^]
MSI47"O#U"J$O4H]QP$O@(&V'Q#XAUZ[;?=JZV,1CGO15\:I5.24KP]''$XZO
M545,**M0AL5MK=39"^LMCBX)L40V5E9-!D!A4,!4TT2*J><X54,;8A2D-O\`
M?J<D%#WB8`'<1`2AM\QMA#Q`1`1V$1^WQT!Y7+YHQ%$SQXT:@Y6(U;>H<HMC
M*NE0'M;I'653\Y538!*F3<YMOCH#U`)RB(]Z@[COVF,(@`_';?J'\>F@`(F'
M^<_7;<`.</`=]OQ;AU^S0'8#F#P$=OL[C#_Q'<-M`<`<P;[&-U^TQC;?=W"(
MAOH#PO'S&+;J/9.0;,6B)-UG4@Z0;()D(!C_`#.'!DRAX"([F\.OW@>2!GHB
MS1;2=K\JUEHEZ"OHY*-7\YB\*BL=!51!4``BR8*I&*!@[@\>T?`=`'(G,.^Y
MC=0VV[C;?PWV$1_;OH#KXE[=@[>GRAT#<``H#N&PAL`:`'B42#L9,2@44S@!
MR"``(;"4P#OOOU^W;0!>WB(EHJ*[2*BVJXF$YEF\<R15,<WXCF430*<3C\1W
MT`8B8P@`&,8WCON.W=X_B`O:7IO\`#PT!P'<'4#G`>XIAV,/7M+V["'X=C!X
M]/'0'(F,/\YP_:!C?XB/CH#@.FW4>GQ$1$WCOU,/S"/[1'?0`'??<#'+]@%.
M8I0^W8N_:.X_:`Z``=P?]10?O.(_?U\>HC^[X:`[=Y_\QO'?Q'[O#PVV^'[_
M`!ZZ`Z`&W[?\-1DDE5R>71&\R*K4`@4?$H#J+EJN"N3N6A*JRI\#J)^G:#M)
M_E#4N/XG^LAFN/XGL_:#M)_E#3'\3_6,UQ_$]G[0;??JBBW2X/5JM[J?K*_F
M(WX42IR``'0-5&M1J43`IJ]SUJY$13D`$=]NH[;[?$?N_=J8@0`SS,4JT<BJ
M%#V=6-:5C#46G=[I+*MO4O',K(.41K%/02;)*OI!9VN1-8C=,JAC"8^P!L.@
M)CX_R-5,HUU*V4U\M(PR[U['^<NT78KHO8]0$W;9PU<E(L@HB(AN!@#H.@&F
MR$_P9DS(%*Q9;5G$Y<8>36MU=81II=-JUDH1,7#@CR6CREC?,1(A_4044-UV
M`W:/30#UVNXUND0KJR6R6:PD,T,0J[QV;;^NMMZ=J@W3[W+EZZ,;9)!,AE3C
MX%T`55+(U9N;N2C(L\FSF(ELP?/X2=B7D++HQTH0YXV2!B](111@]*0>Q0NX
M`(;&[1Z:`;[D'F=/#U'<R<3]*D[M(.X^+JU<>KF4/(O)!<J0J*,6:Y)!9LDC
MW#\G4QQ*`;B(:`/<9YAJ^0EWM<1<O&=YKK"-7M=<EH.5KSYFL[02`SQJPF$R
M.58Q9R803/N8=A#?QT`U/,R41+B-.GI,6K^P9"M4'4JZDZ1(L=F[<NBJ/)=L
M)RF%!6-9D,/FAMV@?Q`!'0"KQCE/$40ZJ&#:U-KJ2T574H^$$T1)-X>;3@FX
MHR"T--+MDF$J`KMU3BHB8Z9QW$IA#KH"0ZAR))JK*G(DB@4YU5E3D323(F43
MJ'.H<Q2D(F0!,81$```W'0#/'SSC0UKK5*CY9]-V&V/EV<2VAX>0=MC)-DU5
M'4HJ_.BBS&';%1-WN$CJD`0VZZ`4>0LHTC%L*I/W.8^G,2[^61NU<R#UR4H)
MB=5LQ:)J.%&R(*E\Q;8$D]_F,&@$Q&\@,63%S@Z#%3Z[ZR6*-"3BT$(J0%DJ
MF,>24,T6D11!FWDD6"A3J(',!TA$"GV,.V@#O(N7Z#BIBU?729,Q*]<(MFS5
MFS<2;Y0Z[CTI%3-61%3HM@<?(*A^TO?L4-S#MH`B4Y"8E1MC:FJ6@I91VR?O
MT'IF+U.OG2C&ZKI^0E@41)%K+-$4#^8":AP*<HD$0/L70J-C<Y*IP#C'^8Z%
MDZ3LL/49%^ZDJFHU+,M9"&E(=5)-]YGHW*!)-LV.NV<"D;M$``>FXAL("(@Y
MCFI51P)26C(1@YE)A\UC(UF4#.GSU8B#9$!$I2@90X@`G.<X%*4-S&,(``"(
M@`B0;JM9HH=PO#S'];>2DG.QL*6>E%`A9!G'1C)55-)LF^=2"351%V\!4IT2
M>6/>00,`[:`=4H@8`,'@/[0';8=A`=A$-P$-`<Z`&@!H`:`&@!H`:`+Y:30A
M8F4FG0'%M#1KZ6<@G^,4(YJJ\6`H;#N)DT1#]^@*[\*R,/%U^Q9^F$D[IF3,
M4W./L?TMFX*_?HE,Z=QL4U;1Y#G-&E3;I`9Z]5*1-JS)V@H4!$#`2UPYC\F'
ML8MH>8>MCR@*2MMNDF7M08A,S"QI.<7;G2`@%8QQ1\HH_P`R:>_QT!'[C2M7
M[_D2X9428IHIN4'E;QQ"-$@495.AQ;U5N9^_.7^A&S-S?G54*4=UUB$4.8>W
M0"CR$V5N'*S'E;L1_+HV/J')Y-;M':Q$XJ0L#=ZI&HOY`5=T52PI@3$1/OV`
M3?IN(Z`^F$/79&S?EK.;<%4:0[C8S'E'=G\TH65A".R*/IYJ541*:,,]1.1-
M4`[3B8XAN`:`++HWA<C<MJ/51)'`QQ#6E[_95Q!N"KR:4.FC!LW3@X%.=**3
M434#O$03*<=MMQT`9X?BW%\Y`99SJU[R4U2-8X]ILA\Y"V;Z09JE,S;$3=HJ
MQ*+EF*22@?*<W<)>A=`)#*:,#E3D<UC[7+M8K&6`*\VG+:^?/R1\>M9;.LEZ
M2&<NS+(II%60(D"H"/SI]Q!`0..@'%90260^1L1=H8&GY'PU3%J[&R#/TX14
MK;9Y-55RRA%D"BW7CJ_$F*FL9(1*FHIV!X:`+\E9(K,_F4^*K1/-X:ETNNL+
M9;8HSDY7=\GI)R@%=J35HB(.91BS25!RZ;)E/ZHPIIG#L`V@$5Q]MK3+F7K9
MEB5:^F5;,7E#QI6FR2:_Y/IT$L!Y:3EQ;"*<0O,/%"H(A_UE/,33#M((Z`.^
M6#16ZS6/<*5DK9M;,FR79.2Z2)#/HS'E=>$DY!110H`;T!9,/.,F(]BJB)>[
M?IH"656IM;J$/"PD'&-$6D&U]*Q7,DDL\$5"@5X[4>F`RZCN0.`G<'$W<J8P
M]V_AH"&>7:\USOG-CBN-,$94Z.E&W/-=A9+)I+NW3=LHE6ZLK(E'9%9I'F,<
MH%,44/4**]#)@;0"":NJG9)J[<EK&P;!A;"4<XJ6'*NFD!8^;=0)SM$I%-D/
M<DH@YEW!0;CVF$ZIR]^XI;#`Y,:^!$3BI(;BG$`C5K%:Y9<\C?+]-?FN\2Y4
MB*QQ9*61(YCJU'2B8BB]2K3%4B*X)"9-%P<2=PB7I$EFY>@;M_G.H2EDR??K
M2["8C,12LC7,=XU0,51Y(S<(U\V;O4G']H]A3.0\AJ[7`4&2"2AR#YIP#0H"
MIXC"$[$W'(LZX^IWW)<FUMME>-2>;&0T8Y(="KU-!ZF`(`]8Q"":Z[8@B*9%
M4Q4V,.V@)B_P^WH`!U'J([``!U'0`T`-`#0`T`-`#0`T!\'7IO2N?6^G]'Y"
MOJ_5]GI?3=A@7]1Y@@EY/E;]W?\`+MXZ`:;'#7!39Y(?I*.,1D#F55E@I#VN
MO7HD\W=4KLT0X7<(H^=OWD'9/N\0T`Z4D#(T<]+)"T"-%HN#_P!<9(C+T/E&
M]8#HRX"@5L+;N`XG^4";B.V@$M0$L=HUY)'&GY0-64W`^2-*<1BT,+G?<>Y>
M'44167+N&^YA,.W70'@O[;%3GT)<CFI(%(1RK&!;W<0S-Z<O:,AZ120705.R
M$.T%DP[DQZ=X>&@#YS-0M<K"4LP:N9.&;,2J1C*G0KV<%TU*B)V;>&C:ZT>"
M9JHD4I4C)E!$/'<-]`0@P)^F$^GE*R9G&KQV1K)D&2EK#6+^5"&EJO$(AY,-
M%*HSYV:J:"D?W'.0NZ9B"7N#8`T!/F+^G?3F/T?T`Q/IDOI@QGD!&BQ[?[;T
M0-/[4&WE;=OE_)MX:`;V=1P^M'79.Q_IR6,4?,?U%^JN(%%KZX/)^GC;UEET
MB(O3%!/R`>;'`.WMWWT`L:R6M!7XPM1^A#6`;;1'Y:,R&"!H`B`!'*1XF9G1
MWWW,0=A-OH!)KHXA#(QG+G]/OU5&-23$B[F"&\FB2IB*`@V55^K)M/3]X=X)
M]ID]^NV^P'KH"6,D(U\GB\*2:*"14/*?DIQ#N&OU<ZIS*C(JQ*JR9G?<)OD5
M,)RCN``&@#94E-"V-Q<#737GZ*J1IZA2-_-0USS#'=BV*8?JA8<'8['$H"E\
M!'?0"H+X=.WQ'\`FV$=QZ@'<(EW'X`/30"2BBT('-O\`I`50KX78GOWTQ2*4
M="_](<%"VT4#"L546'40=@!O*W^'70!#(H8?5QT#>0''A<4]B(%,X<0:5%%`
MCSN1[''J$X8A!DPZ;*"`J[AU'IH!;P18,(>-+71BQ@2MR%AQA!;?3/2;AY1F
M)F`^C.B`[=OE[E'X]>N@&N1:X"WR`5M^E6[HCX^3/*?UL5`;G7*20"VJ$<"J
MQ0%P`"H5P*29%?$.[KH!P*<2H)UR-)0QKPU0B7;$C5%&"D`*(#L/H#Q9CL3!
0W;]PE$PB;Q'0"GT`-`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
